ArticleProceedings of the National Academy of Sciences of the United States of America2016
Reporter nanoparticle that monitors its anticancer efficacy in real time.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Protease-Triggered Chromogenic Release From Peptide-Modified Calcium Carbonate Microspheres Enables Colorimetric Detection of Porphyromonas gingivalis Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Activating a B cell immune response regresses immunologically cold tumours.Nature nanotechnology · 2026Article
- Holography Meets Theranostics: DFT/TDDFT Insights into Ru-NO@MInternational journal of molecular sciences · 2025Article
- Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer.Exploration (Beijing, China) · 2025Review
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- Cancer immunotherapy and its facilitation by nanomedicine.Biomarker research · 2024Review
- Caspase-3-Responsive, Fluorogenic Bivalent Bottlebrush Polymers.ACS macro letters · 2024Article
- Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes.ACS omega · 2023Review
- The Role of Immune Checkpoint Inhibitors in Cancer Therapy.Clinics and practice · 2022Review
- Selenium Nanoparticles Synergistically Stabilized by Starch Microgel and EGCG: Synthesis, Characterization, and Bioactivity.Foods (Basel, Switzerland) · 2022Article
- Nanotheranostic Strategies for Cancer Immunotherapy.Small methods · 2022Review
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Broad-Spectrum Theranostics and Biomedical Application of Functionalized Nanomaterials.Polymers · 2022Review
- Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy.Biomaterials · 2021Article
- Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy.Frontiers in bioengineering and biotechnology · 2021Review
- Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy.Science advances · 2020Article
- Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems.Polymer chemistry · 2020Article
- Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Active transcytosis and new opportunities for cancer nanomedicine.Nature materials · 2020Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
The ability to monitor the efficacy of an anticancer treatment in real time can have a critical effect on the outcome. Currently, clinical readouts of efficacy rely on indirect or anatomic measurements, which occur over prolonged time scales postchemotherapy or postimmunotherapy and may not be concordant with the actual effect. Here we describe the biology-inspired engineering of a simple 2-in-1 reporter nanoparticle that not only delivers a cytotoxic or an immunotherapy payload to the tumor but also reports back on the efficacy in real time. The reporter nanoparticles are engineered from a novel two-staged stimuli-responsive polymeric material with an optimal ratio of an enzyme-cleavable drug or immunotherapy (effector elements) and a drug function-activatable reporter element. The spatiotemporally constrained delivery of the effector and the reporter elements in a single nanoparticle produces maximum signal enhancement due to the availability of the reporter element in the same cell as the drug, thereby effectively capturing the temporal apoptosis process. Using chemotherapy-sensitive and chemotherapy-resistant tumors in vivo, we show that the reporter nanoparticles can provide a real-time noninvasive readout of tumor response to chemotherapy. The reporter nanoparticle can also monitor the efficacy of immune checkpoint inhibition in melanoma. The self-reporting capability, for the first time to our knowledge, captures an anticancer nanoparticle in action in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.